Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pacritinib + Ibrutinib in Relapsed/Refractory CLL/SLL
NCT02677948Phase 2Withdrawn
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Oct 2016
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pacritinib in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by University of Michigan Rogel Cancer Center. Planned start Oct 2016; status: withdrawn.
02
Drugs
pacritinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT02677948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02677948.